RxDoctor Payments Data

Michael Richter, MD

Internal Medicine · Rego Park, NYNPI 1609978329

Payments from drug & device makers

$2,377in general payments, 2019–2025

Across 75 payments — averaging $31.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Alkermes, Inc.$371
  • Orexo US, Inc.$177
  • Lilly USA, LLC$128
  • Boehringer Ingelheim$95
  • Pfizer$94
  • plus $293 from 9 others

What the payments were for

  • Food & beverage$2,377100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,377 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$80,950
Medicare patients
110
Services billed
826

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide29$56,342
EliquisApixaban13$20,676
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl91$17,355
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$10,414
SuboxoneBuprenorphine Hcl/Naloxone Hcl18$10,386
JardianceEmpagliflozin13$7,358
ZubsolvBuprenorphine Hcl/Naloxone Hcl13$3,813
Rosuvastatin Calcium170$2,865
Varenicline Tartrate11$2,444
Risedronate Sodium26$2,420
Albuterol Sulfate HfaAlbuterol Sulfate42$1,930
Metoprolol Succinate99$1,712
SynthroidLevothyroxine Sodium30$1,680
Olmesartan Medoxomil38$1,481
Tamsulosin Hcl56$1,023

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$128$56,34229 claims
PfizerEliquis$94$20,67613 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$19$17,35591 claims
Indivior Inc.Suboxone$22$10,38618 claims
Boehringer IngelheimJardiance$95$7,35813 claims
Orexo US, Inc.Zubsolv$177$3,81313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rego Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →